Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Total Current Liabilities (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Total Current Liabilities for 15 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 27.02% to $1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a 27.02% decrease, with the full-year FY2024 number at $2.8 million, down 33.54% from a year prior.
  • Total Current Liabilities was $1.4 million for Q3 2025 at NovaBay Pharmaceuticals, down from $2.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $6.1 million in Q2 2023 to a low of $1.4 million in Q3 2025.
  • A 5-year average of $3.5 million and a median of $3.6 million in 2024 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 65.87% in 2023, then tumbled 56.6% in 2024.
  • NovaBay Pharmaceuticals' Total Current Liabilities stood at $3.4 million in 2021, then grew by 23.68% to $4.3 million in 2022, then rose by 0.49% to $4.3 million in 2023, then crashed by 33.54% to $2.8 million in 2024, then crashed by 49.07% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Total Current Liabilities are $1.4 million (Q3 2025), $2.1 million (Q2 2025), and $3.1 million (Q1 2025).